Malignant pleural mesothelioma is an aggressive malignancy of the pleural surface,
predominantly caused by prior asbestos exposure. There is a global epidemic of malignant …

Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000
people each year in the United States. Although MPM is an extremely difficult disease to …

Purpose: Patients with malignant pleural mesothelioma, a rapidly progressing malignancy
with a median survival time of 6 to 9 months, have previously responded poorly to …

Objectives: Our aim was to identify prognostic variables for long-term postoperative survival
in trimodality management of malignant pleural mesothelioma. Methods: From 1980 to 1997 …

Background: Surgical resection of malignant pleural mesothelioma is reported to have up to
an 80% rate of local recurrence. We performed a phase II trial of high-dose hemithoracic …

Purpose: Amatuximab is a chimeric monoclonal antibody to mesothelin, a cell surface
glycoprotein highly expressed in malignant pleural mesothelioma (MPM). On the basis of its …

Introduction Malignant pleural mesothelioma (MPM) is an incurable malignant disease,
which results from chronic exposition to asbestos in at least 70% of the cases. Fibroblast …

Background. The factors influencing outcome after resection of malignant pleural
mesothelioma (MPM) are controversial. This analysis of a prospective surgical database …

Introduction: This study characterizes the overall survival (OS) and variables affecting OS in
patients with malignant pleural mesothelioma. Methods: A total of 9701 patients with …

The incidence of malignant pleural mesothelioma (MPM) has risen for some decades and is
expected to peak between 2010 and 2020. Up to now, no single treatment has been proven …